Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.

Drugs·2016
Same author

Erratum to: Cariprazine: First Global Approval.

Drugs·2016
Same author

Capsaicin 8 % Patch: A Review in Peripheral Neuropathic Pain.

Drugs·2015
Same author

Evogliptin: First Global Approval.

Drugs·2015
Same author

Cariprazine: First Global Approval.

Drugs·2015
Same author

Vilazodone: a review in major depressive disorder in adults.

Drugs·2015

Related Experiment Video

Updated: Jun 26, 2026

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

Adalimumab: in plaque psoriasis.

Katherine F Croom1, Paul L McCormack

  • 1Wolters Kluwer Health/Adis, Auckland, New Zealand.

American Journal of Clinical Dermatology
|January 28, 2009
PubMed
Summary

Adalimumab effectively treats moderate-to-severe chronic plaque psoriasis, improving symptoms and quality of life. Long-term studies show sustained efficacy and good tolerability in psoriasis patients.

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Psoriasis is a chronic inflammatory skin condition.
  • Tumor necrosis factor (TNF) plays a key role in psoriasis pathogenesis.
  • Adalimumab targets TNF, offering a potential therapeutic option.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of adalimumab in patients with moderate-to-severe chronic plaque psoriasis.
  • To assess the long-term efficacy and durability of response to adalimumab treatment.
  • To compare the effectiveness of adalimumab with placebo and methotrexate.

Main Methods:

  • Several randomized, double-blind clinical trials were conducted, including pivotal trials REVEAL and CHAMPION.
  • Efficacy was assessed using the Psoriasis Area and Severity Index (PASI) 75 response.

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Related Experiment Videos

Last Updated: Jun 26, 2026

Measuring Psoriasis Severity at Home
02:28

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

  • Health-related quality of life measures were also utilized.

    • Main Results:

    • Adalimumab demonstrated significantly greater efficacy than placebo and methotrexate in relieving psoriasis signs and symptoms after 16 weeks.
    • Long-term open-label extension studies showed sustained efficacy for up to 2 years.
    • Patients continuing adalimumab maintained response better than those switched to placebo.
    • Adalimumab significantly improved quality of life compared to placebo or methotrexate.
    • The safety profile was generally well-tolerated and consistent with previous findings.

    Conclusions:

    • Adalimumab is a highly effective treatment for moderate-to-severe chronic plaque psoriasis.
    • Sustained efficacy and significant improvements in quality of life are key benefits.
    • Adalimumab offers a well-tolerated therapeutic option for long-term psoriasis management.